F.M. Muggia and H.A. Burris, Clinical Development of Topoisomerase-Interactive Drugs.
D. Peereboom, M. Charron, and S.H. Kaufmann, Topoisomerases in Human Leukemia.
D. Costin and M. Potmesil, Preclinical and Clinical Development of Camptothecins.
Y. Pommier, A. Tanizawa, and K.W. Kohn, Mechanisms of Topoisomerase I Inhibition by Anticancer Drugs.
T. Andoh and K. Okada, Drug Resistance Mechanisms of Topoisomerase I Drugs.
N. Osheroff, A.H. Corbett, and M.J. Robinson, Mechanism of Action of Topoisomerase II-Targeted Antineoplastic Drugs.
P. Darpa, Determinants of Sensitivity to Topoisomerase-Targeting Antihumor Drugs.
W.T. Beck, M.K. Danks, J.S. Wolverton, M. Chen, B. Granzen, R. Kim,and D.P. Suttle, Resistance of Mammalian Tumor Cells to Inhibitors of DNA Topoisomerase II.
K.N. Kreuzer, A Bacteriophage Model System for Studying Topoisomerase Inhibitors.
T.A. Shapiro, Drugs Affecting Trypanosome Topoisomerases.
J.L.Nitiss, Yeast as a Genetic Model System for Studying Topoisomerase Inhibitors.
L.L. Shen and J.M. Fostel, DNA Topoisomerase Inhibitors as Antifungal Agents.
A.Y. Chen and L.F. Liu, Design of Topoisomerase Inhibitors to Overcome MDR1-Mediated Drug Resistance. Appendices:
J.C. Wang, An Introduction to DNA Supercoiling and DNA Topoisomerase-Catalyzed Linking Number Changes of Supercoiled DNA.
P.R. Caron and J.C. Wang, Alignment of Primary Sequences of DNA Topoisomerases.
Contents of Previous Volumes.